Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, today announces the appointment of Dr David Chiswell OBE as a Non-Executive Director of Bond 2 Development 2 GP,
March 14, 2019
· 2 min read